Supernus Pharmaceuticals Inc

NASDAQ:SUPN  
31.68
+0.61 (+1.96%)
Products

Supernus Announces Positive Results From Phase Iii Study For Spn-812 In Adults With Adhd

Published: 12/22/2020 23:28 GMT
Supernus Pharmaceuticals Inc (SUPN) - Supernus Announces Positive Results From Phase Iii Study for Spn-812 in Adults With Adhd.
Supernus Pharmaceuticals Inc - Met Primary Endpoint With Robust Statistical Significance From Phase Iii Study for Spn-812.
Supernus Pharmaceuticals - Will Be Meeting With FDA in January 2021 to Discuss Crl for Spn-812.
Supernus Pharmaceuticals - Plans to Submit a Supplemental NDA (snda) to FDA for Spn-812 in Adults in Second Half of 2021.